Shadi Setayeshi and Seyed Ahmad Rasoulinejad* Pages 1 - 8 ( 8 )
Retinal Degenerative Diseases [RDDs] are irreversible ocular damages categorized as retinopathies. RDDs affect about 0.05% of individuals worldwide. The degenerations of RPE cells are involved in inherited and age-related RDDs. After the invention of induced Pluripotent Stem Cells [iPSC] by Yamanaka, a promising avenue has been opened to regenerative medicine and disease modeling. Retinal pigment epithelium [RPE] degeneration related-RDDs are also affected by iPSCs. IPSC-derived RPE cells created a novel method for treating the RPE degeneration related- RDDs and retinal diseases modeling to find a new therapeutic approach or drug development. There are various studies based on iPSC-derived RPE cells reporting the investigation of the role of a specific mutation, protein, signaling pathway, etc., responsible for a type of RDD. Furthermore, iPSC-based RPE therapy is expanded to include some clinical trials. Despite the incredible growth rate in iPSC-based studies on RPE-related diseases, there are some challenges, i.e., teratoma formation potential of iPSCs, an expensive procedure of iPSC-based regeneration of RPEs, lack of a universal protocol or cellular product applicable in all patients, etc. This article reviews the iPSC-based RPE generation and their therapeutic applications, studies on RPE-related molecular and cellular pathophysiologic features of RDD in the iPSC-based models, future perspectives, and the challenges ahead.
Induced Pluripotent Stem Cells, Regenerative Medicine, Retinal Degenerative Diseases, Retinal pigment epithelium.
Department of Medical Biotechnology, Faculty of Medicine, Babol University of Medical Sciences, Babol,, Department of Ophthalmology, Ayatollah Rouhani Hospital, Babol University of Medical Sciences, Babol